Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geyer

Showing results (241-250 of 278) with videos related to

Pageof 28
Sort By:
Leukemia & Lymphoma|July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
British Journal of Haematology|February 16, 2008
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialTait D Shanafelt, Susan M Geyer, Nancy D Bone, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disordersIrene M Ghobrial, Thomas M Habermann, Matthew J Maurer, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancerSteven E Schild, Philip J Stella, Susan M Geyer, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Bone Marrow Transplantation|July 15, 2003
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphomaR Howe, I N M Micallef, D J Inwards, et al.
Blood|July 18, 2008
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab eraThomas M Habermann, Sophia S Wang, Matthew J Maurer, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Blood|March 1, 2007
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survivalJames R Cerhan, Sophia Wang, Matthew J Maurer, et al.
Pageof 28

Showing results (241-250 of 278) with videos related to

Sort By:
Pageof 28
Leukemia & Lymphoma|July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
British Journal of Haematology|February 16, 2008
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialTait D Shanafelt, Susan M Geyer, Nancy D Bone, et al.
Leukemia & Lymphoma|June 24, 2008
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Susan M Geyer, Paul J Kurtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disordersIrene M Ghobrial, Thomas M Habermann, Matthew J Maurer, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancerSteven E Schild, Philip J Stella, Susan M Geyer, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Bone Marrow Transplantation|July 15, 2003
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphomaR Howe, I N M Micallef, D J Inwards, et al.
Blood|July 18, 2008
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab eraThomas M Habermann, Sophia S Wang, Matthew J Maurer, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Blood|March 1, 2007
Prognostic significance of host immune gene polymorphisms in follicular lymphoma survivalJames R Cerhan, Sophia Wang, Matthew J Maurer, et al.
Pageof 28